REGiMMUNE offers following partnering opportunities;

1. Co-development partner for current pipelines

2. New development program in allergy and autoimmune disease area employing our reVax technology.

For companies with specific target antigens in those area, we also offer target validation program, which consists of;

Step 1: delivering prototype molecule
Step 2: validation in in vitro and in vivo models (optional)
Step 3: Further licensing discussion
　
　
For partnering opportunities, please contact:
　
Haru MORITA
Chief Executive Officer
REGiMMUNE Corporation
3-12-5 Shibaura, Ishizaka Bldg. 6F
Minato-ku, Tokyo 108-0023
Tel: +81-3-3456-0820
Fax: +81-3-3456-0821

For e-mail inquiries, please mail us from contact form